World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Original Article

Volume 5, Number 5-6, December 2014, pages 204-209

A Retrospective Study of Efficacy and Safety of Albumin-Bound Paclitaxel in Metastatic Breast Cancer

Figures

Figure 1.
Figure 1. Survival curves for patients receiving q3w nab-paclitaxel.
Figure 2.
Figure 2. Survival curves for patients who achieved and did not achieve clinical benefit from nab-paclitaxel.

Tables

Table 1. Demographic and Treatment Characteristics of Patients With MBC Receiving Nab-Paclitaxel
 
Variable value
ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; OS: overall survival.
Patients (n)14
Age (years)
  Mean58.0
  Range39 - 70
Receptor status (%)
  ER-positive71.42
  PR-positive57.14
  HER2-positive14.28
Sites of metastasis (%)
  Bone only14.28
  Liver only7.14
  Lung only7.14
Multiple sites71.44
Current line of chemotherapy for advanced disease (median (range))3 (1 - 6)
Previous taxane exposure (n (%))10 (71.42)
  Adjuvant2 (20)
  Metastatic7 (70)
  Adjuvant and metastatic1 (10)
Median duration (months)4.5

 

Table 2. Clinical Outcomes Data in Patients With MBC Receiving Nab-Paclitaxel (q3w) Schedule
 
VariableNab-paclitaxel schedule q3w (260 mg/m2)
Patients (n)14
Overall response (%)43
  Complete7.14
  Partial35.71
Development of neuropathy (%)35.7
Overall survival (months)
  Median11.9
  Interquartile range7.7 - 21.8

 

Table 3. Results of Cox Proportional Hazards Analysis on OS
 
VariableHR95% CIP-valueImpact on survival
Line of chemotherapy1.391.05 - 1.840.021↑ Risk by 39% per line
Achievement of clinical benefit0.140.06 - 0.330.001↓ Risk by 86%